Distinct and Convergent Roles of the Synovial Sarcoma X Breakpoint Family of Cancer-Testis Antigens in Ovarian Cancer.

Kelly C Grayson, Holly N Wilkinson, John D Wright, Stephen J Archibald, Matthew J Hardman, Barbara-Ann Guinn

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kelly C GraysonCentre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, UK.ORCID 0009-0000-4602-0363

Holly N WilkinsonWound Innovation Institute, University of Hull, Hull HU6 7RX, UK.ORCID 0000-0002-8453-7264

John D WrightCentre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, UK.

Stephen J ArchibaldCentre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, UK.

Matthew J HardmanWound Innovation Institute, University of Hull, Hull HU6 7RX, UK.

Barbara-Ann GuinnCentre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, UK.ORCID 0000-0003-0639-4541

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OC) is a leading cause of death in women, with limited advances in diagnosis and treatment over the past decade. The Synovial Sarcoma, X Breakpoint (SSX) family of cancer-testis antigens represent promising biomarkers and immunotherapeutic targets; however, the functions of individual SSX family members remain poorly defined due to their high sequence similarity. We investigated the roles of SSX2A, SSX2B and SSX3 using RNA sequencing, in vitro and in vivo assays. Pathway analysis revealed involvement in nucleosome assembly, calcium signalling, and cellular stress responses, alongside increased OC cell proliferation in vitro following overexpression. Additionally, SSX variants altered key epithelial-mesenchymal transition (EMT) associated markers, including upregulation of the transcription factor, SLUG. Integration with patient transcriptomic datasets identified several SSX regulated genes associated with overall survival (OS). These findings suggest that SSX family members are not functionally redundant and may contribute to OC progression and clinical outcome.

Indexed as

Antigens, NeoplasmNeoplasm ProteinsOvarian NeoplasmsRepressor ProteinsAnimalsCell Line, TumorCell ProliferationEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansAntigens, NeoplasmNeoplasm ProteinsRepressor Proteinssynovial sarcoma X breakpoint proteinscancer-testis antigenovarian cancerRNA sequencingSSXsynovial sarcoma X breakpoint

Identifiers

PMID42883856

DOI10.3390/ijms27198608

PMCPMC13665215

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.